Merck has teamed up with BGI, the world’s largest genomics centre, to discover and develop of biomarkers and genomic technologies.

Under the agreement, scientists from Merck and BGI will work together to identify and characterise biomarkers, with an emphasis on drug discovery, drug development and diagnostics applications for a wide range of therapeutic areas.

Merck Research Laboratories vice-president Jeffrey Chodakewitz said that the companies “hope to apply BGI’s comprehensive next-gen sequencing solutions to develop important new tools to aid drug development and enable effective tailoring of medicines to those patients most likely to respond”.

Merck and BGI will each be permitted to propose projects and will provide resources, expertise, samples and research material.